4//SEC Filing
FFI FUND LTD 4
Accession 0001104659-21-117993
CIK 0001817944other
Filed
Sep 20, 8:00 PM ET
Accepted
Sep 21, 6:38 PM ET
Size
11.8 KB
Accession
0001104659-21-117993
Insider Transaction Report
Form 4
FYI Ltd
10% Owner
Transactions
- Sale
Common Stock
2021-09-17$9.20/sh−127,360$1,171,712→ 2,102,495 total(indirect: See footnote)
Olifant Fund, Ltd.
10% Owner
Transactions
- Sale
Common Stock
2021-09-17$9.20/sh−127,360$1,171,712→ 2,102,495 total(indirect: See footnote)
FFI FUND LTD
10% Owner
Transactions
- Sale
Common Stock
2021-09-17$9.20/sh−127,360$1,171,712→ 2,102,495 total(indirect: See footnote)
Bracebridge Capital, LLC
10% Owner
Transactions
- Sale
Common Stock
2021-09-17$9.20/sh−127,360$1,171,712→ 2,102,495 total(indirect: See footnote)
Footnotes (3)
- [F1]Shares of common stock, $0.0001 par value per share ("Shares") of Clarus Therapeutics Holdings, Inc. (the "Issuer"), were sold as follows: (i) 92,973 Shares were sold by FFI Fund Ltd. ("FFI"), (ii) 17,830 Shares were sold by FYI Ltd. ("FYI"), and (iii) 16,557 Shares were sold by Olifant Fund, Ltd. (together with FFI and FYI, the "Bracebridge Funds"). Bracebridge Capital, LLC (the "Investment Manager") is the investment manager of each of the Bracebridge Funds and has the authority to vote and dispose of all the Shares reflected herein.
- [F2]This price is a weighted-average price. These Shares were sold in multiple transactions at prices ranging from $9.05 to $9.34, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the ranges set forth in this explanatory note.
- [F3]Each of the Bracebridge Funds and the Investment Manager disclaims beneficial ownership of the Shares except to the extent of any pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the Shares reported herein for purposes of Section 16 of the Securities Exchange Act of 1934 or for any other purpose.
Documents
Issuer
Clarus Therapeutics Holdings, Inc.
CIK 0001817944
Entity typeother
Related Parties
1- filerCIK 0001081816
Filing Metadata
- Form type
- 4
- Filed
- Sep 20, 8:00 PM ET
- Accepted
- Sep 21, 6:38 PM ET
- Size
- 11.8 KB